Sustained Release Excipients Market Overview
The Sustained Release Excipients Market is expanding as pharmaceutical companies increasingly adopt advanced drug delivery systems designed to improve therapeutic efficacy, bioavailability, patient compliance, and convenience. Rising chronic disease prevalence, technological advancements in formulation science, growing demand for patient-centric medicines, and increased pharmaceutical R&D investment are supporting market growth.
According to the Market Research Future report updated August 24, 2026, the global Sustained Release Excipients Market was valued at USD 1.5 Billion in 2024 and is projected to grow from USD 1.62 Billion in 2025 to USD 3.498 Billion by 2035, registering a CAGR of 8.0% during 2025–2035. North America remains the largest regional market, supported by significant pharmaceutical companies and increasing R&D activity, while Asia-Pacific is identified as the fastest-growing region. Gelatin is the dominant product type, Polymers are the fastest-growing product category, Oral administration holds the largest route of administration, and Targeted Delivery is the leading technology segment.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/reports/sustained-release-excipients-market-22077
Key players driving innovation and competitiveness in the Sustained Release Excipients Market include:
BASF SE
Evonik Industries AG
Ashland Global Holdings Inc.
Dow Inc.
JRS Pharma
Colorcon Inc.
FMC Corporation
Gattefossé
Merck KGaA
Shin-Etsu Chemical Co., Ltd.
The market is being shaped by increasing demand for advanced drug delivery systems, rising chronic disease prevalence, and the growing emphasis on patient-centric treatment. New polymers and biocompatible materials are improving sustained-release performance, while regulatory support for innovative formulations is encouraging pharmaceutical companies to invest in new excipient technologies. Advanced manufacturing approaches, including nanotechnology and 3D printing, are also supporting more precise drug-release profiles.
The Sustained Release Excipients Market can be segmented by Product Type into Gelatin, Polymers, Minerals, Sugars, and Others. By Route of Administration, it includes Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Others. By Technology, it covers Targeted Delivery, Microencapsulation, Wurster Technique, and Others. Regionally, the market covers North America, Europe, Asia-Pacific, and the Rest of the World.
The growing need for controlled drug delivery is creating opportunities for excipient manufacturers, pharmaceutical companies, specialty chemical producers, and drug-development organizations. Biodegradable excipients, novel polymer systems, specialized formulations for chronic diseases, and partnerships between excipient suppliers and pharmaceutical manufacturers can support future innovation.
Recent Developments and Market Trends:
Growing demand for patient-centric drug delivery systems is encouraging the development of excipients that can improve medication adherence and therapeutic outcomes.
Advancements in material science are supporting innovative polymers and biocompatible materials with improved controlled-release characteristics.
Regulatory support for novel drug formulations is creating a favorable environment for sustained-release excipient innovation.
Pharmaceutical companies are increasing R&D investments in excipients that can improve drug solubility, bioavailability, and controlled release.
Advanced technologies such as nanotechnology and 3D printing are enabling more precise drug-release profiles and supporting personalized medicine applications.
Reasons to Buy the Report:
Provides comprehensive insights into the Sustained Release Excipients Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across gelatin, polymers, minerals, sugars, and other excipient categories.
Offers detailed segmentation analysis across product type, route of administration, technology, and geographic markets.
Includes competitive intelligence covering major pharmaceutical excipient manufacturers and specialty chemical companies.
Supports strategic decisions using market forecasts, chronic disease trends, R&D investment, drug-delivery innovations, regulatory developments, and regional growth opportunities.
Future Outlook:
The future of the Sustained Release Excipients Market will be shaped by rising demand for controlled drug delivery systems, increasing chronic disease prevalence, growing pharmaceutical R&D investment, and the continued shift toward patient-centric therapies. Gelatin is expected to remain an important product category because of its established pharmaceutical applications, while Polymers are positioned as the fastest-growing category due to their versatility and ability to provide tailored release profiles. Oral administration should continue to dominate because of its convenience and strong patient acceptance, while Transdermal and Subcutaneous approaches offer opportunities through advances in non-invasive and extended-release therapies. Targeted Delivery is expected to remain a leading technology, with Microencapsulation providing significant growth potential. North America should retain its leadership position, while Asia-Pacific is expected to record the fastest growth. Market Research Future projects the Sustained Release Excipients Market to reach USD 3.498 Billion by 2035 at a CAGR of 8.0% during 2025–2035.
➤➤Explore Our Latest Related Reports:
